249 related articles for article (PubMed ID: 37845762)
1. Micro-syringe chip-guided intratumoral administration of lipid nanoparticles for targeted anticancer therapy.
Kim J; Song S; Gwak M; Cho H; Yun WS; Hwang N; Kim J; Lee JS; Kim DH; Kim H; Jeon SI; Kim TI; Kim K
Biomater Res; 2023 Oct; 27(1):102. PubMed ID: 37845762
[TBL] [Abstract][Full Text] [Related]
2. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
Hadinoto K; Sundaresan A; Cheow WS
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
[TBL] [Abstract][Full Text] [Related]
3. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
4. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy.
Shim MK; Park J; Yoon HY; Lee S; Um W; Kim JH; Kang SW; Seo JW; Hyun SW; Park JH; Byun Y; Kwon IC; Kim K
J Control Release; 2019 Jan; 294():376-389. PubMed ID: 30550940
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy.
Shim N; Jeon SI; Yang S; Park JY; Jo M; Kim J; Choi J; Yun WS; Kim J; Lee Y; Shim MK; Kim Y; Kim K
Biomaterials; 2022 Oct; 289():121806. PubMed ID: 36156411
[TBL] [Abstract][Full Text] [Related]
6. pH-Triggered Surface Charge Reversed Nanoparticle with Active Targeting To Enhance the Antitumor Activity of Doxorubicin.
Du JB; Cheng Y; Teng ZH; Huan ML; Liu M; Cui H; Zhang BL; Zhou SY
Mol Pharm; 2016 May; 13(5):1711-22. PubMed ID: 26998644
[TBL] [Abstract][Full Text] [Related]
7. Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance.
Kim J; Shim MK; Yang S; Moon Y; Song S; Choi J; Kim J; Kim K
J Control Release; 2021 Feb; 330():920-932. PubMed ID: 33152391
[TBL] [Abstract][Full Text] [Related]
8. Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization.
Wu YW; Lee DY; Lu YL; Delila L; Nebie O; Barro L; Changou CA; Lu LS; Goubran H; Burnouf T
Platelets; 2023 Dec; 34(1):2237134. PubMed ID: 37580876
[TBL] [Abstract][Full Text] [Related]
9. Delivery of Corn-Derived Nanoparticles with Anticancer Activity to Tumor Tissues by Modification with Polyethylene Glycol for Cancer Therapy.
Sasaki D; Kusamori K; Nishikawa M
Pharm Res; 2023 Apr; 40(4):917-926. PubMed ID: 36352200
[TBL] [Abstract][Full Text] [Related]
10. Enhancing the Efficacy and Safety of Doxorubicin against Hepatocellular Carcinoma through a Modular Assembly Approach: The Combination of Polymeric Prodrug Design, Nanoparticle Encapsulation, and Cancer Cell-Specific Drug Targeting.
Xu L; Xu S; Wang H; Zhang J; Chen Z; Pan L; Wang J; Wei X; Xie H; Zhou L; Zheng S; Xu X
ACS Appl Mater Interfaces; 2018 Jan; 10(4):3229-3240. PubMed ID: 29313660
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, Positron Emission Tomography Imaging, and Therapy of Diabody Targeted Drug Lipid Nanoparticles in a Prostate Cancer Murine Model.
Wong P; Li L; Chea J; Delgado MK; Poku E; Szpikowska B; Bowles N; Minnix M; Colcher D; Wong JYC; Shively JE; Yazaki PJ
Cancer Biother Radiopharm; 2017 Sep; 32(7):247-257. PubMed ID: 28910151
[TBL] [Abstract][Full Text] [Related]
12. Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery.
van der Meel R; Chen S; Zaifman J; Kulkarni JA; Zhang XRS; Tam YK; Bally MB; Schiffelers RM; Ciufolini MA; Cullis PR; Tam YYC
Small; 2021 Sep; 17(37):e2103025. PubMed ID: 34337865
[TBL] [Abstract][Full Text] [Related]
13. Design of pH-sensitive methotrexate prodrug-targeted curcumin nanoparticles for efficient dual-drug delivery and combination cancer therapy.
Xie J; Fan Z; Li Y; Zhang Y; Yu F; Su G; Xie L; Hou Z
Int J Nanomedicine; 2018; 13():1381-1398. PubMed ID: 29563794
[TBL] [Abstract][Full Text] [Related]
14. Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy.
Shim MK; Moon Y; Yang S; Kim J; Cho H; Lim S; Yoon HY; Seong JK; Kim K
Biomaterials; 2020 Dec; 261():120347. PubMed ID: 32889501
[TBL] [Abstract][Full Text] [Related]
15. Calcein release behavior from liposomal bilayer; influence of physicochemical/mechanical/structural properties of lipids.
Maherani B; Arab-Tehrany E; Kheirolomoom A; Geny D; Linder M
Biochimie; 2013 Nov; 95(11):2018-33. PubMed ID: 23871914
[TBL] [Abstract][Full Text] [Related]
16. Turning an antiviral into an anticancer drug: nanoparticle delivery of acyclovir monophosphate.
Yao J; Zhang Y; Ramishetti S; Wang Y; Huang L
J Control Release; 2013 Sep; 170(3):414-20. PubMed ID: 23791977
[TBL] [Abstract][Full Text] [Related]
17. Bypassing multidrug resistance in human breast cancer cells with lipid/polymer particle assemblies.
Li B; Xu H; Li Z; Yao M; Xie M; Shen H; Shen S; Wang X; Jin Y
Int J Nanomedicine; 2012; 7():187-97. PubMed ID: 22275834
[TBL] [Abstract][Full Text] [Related]
18. pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells.
Chen HH; Huang WC; Chiang WH; Liu TI; Shen MY; Hsu YH; Lin SC; Chiu HC
Int J Nanomedicine; 2015; 10():5035-48. PubMed ID: 26346762
[TBL] [Abstract][Full Text] [Related]
19. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
[TBL] [Abstract][Full Text] [Related]
20. Small interfering RNA for cancer treatment: overcoming hurdles in delivery.
Charbe NB; Amnerkar ND; Ramesh B; Tambuwala MM; Bakshi HA; Aljabali AAA; Khadse SC; Satheeshkumar R; Satija S; Metha M; Chellappan DK; Shrivastava G; Gupta G; Negi P; Dua K; Zacconi FC
Acta Pharm Sin B; 2020 Nov; 10(11):2075-2109. PubMed ID: 33304780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
